Evaluation of the xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and hiv infection are highly endemic

Clinical Infectious Diseases

Volumn 55, Issue 9, 2012, Pages 1171-1178

  O'Grady, Justin ^a   Bates, Matthew ^a   Chilukutu, Lophina ^a   Mzyece, Judith ^a   Cheelo, Busiku ^a   Chilufya, Moses ^a   Mukonda, Lukundo ^a   Mumba, Maxwell ^a   Tembo, John ^a   Chomba, Mumba ^a   Kapata, Nathan ^a,b   Maeurer, Markus ^c   Rachow, Andrea ^d   Clowes, Petra ^d   Hoelscher, Michael ^d,e   Mwaba, Peter ^a,f   Zumla, Alimuddin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b National Tuberculosis Control Programme   (Zambia)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Mbeya Medical Research Programme   (Tanzania)

^e UNIVERSITY OF MUNICH   (Germany)

^f MINISTRY OF HEALTH   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDEMIC DISEASE; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LABORATORY DEVICE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TERTIARY HEALTH CARE;

ADULT; FEMALE; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TERTIARY CARE CENTERS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; ZAMBIA;

EID: 84867550821     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis631     Document Type: Article

References (30)

1. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010; 10:937-46.
2. WHO. Global tuberculosis control: WHO report 2011. Geneva: World Health Organization, 2011.
3. Migliori GB, Dheda K, Centis R, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health 2010; 15:1052-66.
4. WHO. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva: World Health Organization, 2010.
5. O'Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011; 17:134-41.
6. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a metaanalysis. J Infect 2012; 64:580-8.
7. WHO. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization, 2008.
8. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010.
9. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smearnegative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369:2042-9. (Pubitemid 46908825)
10. Kapata N, Chanda-Kapata P, O'Grady J, et al. Trends of Zambia's tuberculosis burden over the past two decades. Trop Med Int Health 2011; 16:1404-9.
11. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay - a clinical validation study. PLoS One 2011; 6:e20458.
12. Scott LE, McCarthy K, Gous N, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 2011; 8:e1001061.
13. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184:132-40.
14. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819-24.
15. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071-9.
16. Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011; 49:1621-3.
17. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-15.
18. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicenter implementation study. Lancet 2011; 377:1495-505.
19. Bates M, O'Grady J, Mwaba P, et al. Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with noncommunicable diseases in sputum producing adult inpatients. PLoS One 2012; 55:1171-8.
20. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819-24.
21. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
22. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a costeffectiveness analysis. PLoS Med 2011; 8:e1001120.
23. Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60:e1-7.
24. Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a model-based analysis. AIDS 2012; 26:987-95.
25. FIND. Performance of Xpert MTB/RIF version G4 assay. Geneva: Foundation for Innovative New Diagnostics, 2011.
26. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-82.
27. WHO. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "How-to"; practical considerations. Geneva: World Health Organization, 2011.
28. van Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS ONE 2011; 6:e28815.
29. Friedrich SO, Venter A, Kayigire XA, Dawson R, Donald PR, Diacon AH. Suitability of Xpert MTB/RIF and genotype MTBDRplus for patient selection for a tuberculosis clinical trial. J Clin Microbiol 2011; 49:2827-31.
30. Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 60:e1-7.